Potent, Selective and Orally Bioavailable Dihydropyrimidine Inhibitors of Rho Kinase (ROCK1) as Potential Therapeutic Agents for Cardiovascular Diseases

被引：63

作者：

Sehon, Clark A. ^{[1
]}

Wang, Gren Z. ^{[1
]}

Viet, Andrew Q. ^{[1
]}

Goodman, Krista B. ^{[1
]}

Dowdell, Sarah E. ^{[1
]}

Elkins, Patricia A. ^{[3
]}

Semus, Simon F. ^{[3
]}

Evans, Christopher ^{[2
]}

Jolivette, Larry J. ^{[2
]}

Kirkpatrick, Robert B. ^{[4
]}

Dul, Edward ^{[4
]}

Khandekar, Sanjay S. ^{[4
]}

Yi, Tracey ^{[4
]}

Wright, Lois L. ^{[5
]}

Srnith, Gary K. ^{[5
]}

Behm, David J. ^{[6
]}

Bentley, Ross ^{[7
]}

Doe, Christopher P. ^{[7
]}

Hu, Erding ^{[6
]}

Lee, Dennis ^{[1
]}

机构：

[1] GlaxoSmithKline Inc, Dept Med Chem, King Of Prussia, PA 19406 USA

[2] GlaxoSmithKline Inc, Dept Drug Metab & Pharmacokinet, King Of Prussia, PA 19406 USA

[3] GlaxoSmithKline Inc, CVU CEDD, Dept Computat & Struct Sci, King Of Prussia, PA 19406 USA

[4] GlaxoSmithKline Inc, Dept Gene Express & Prot Biochem, King Of Prussia, PA 19406 USA

[5] GlaxoSmithKline Inc, Dept Assay Dev & Compound Profiling, Res Triangle Pk, NC 27709 USA

[6] GlaxoSmithKline Inc, Dept Vasc Biol, King Of Prussia, PA 19406 USA

[7] GlaxoSmithKline Inc, Dept Investigat Biol, King Of Prussia, PA 19406 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2008年 / 51卷 / 21期

关键词：

D O I：

10.1021/jm8005096

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Recent studies using known Rho-associated kinase isoform 1 (ROCK1) inhibitors along with cellular and molecular biology data have revealed a pivotal role of this enzyme in many aspects of cardiovascular function. Here we report a series of ROCK 1 inhibitors which were originally derived from a dihydropyrimidinone core 1. Our efforts focused oil the optimization of dihydropyrimidine 2. which resulted in the identification of a series of dihydropyrimidines with improved pharmacokinetics and P450 properties.

引用

页码：6631 / 6634

页数：4

共 50 条

[41] Inhibitors of HIV-1 attachment. Part 7: Indole-7-carboxamides as potent and orally bioavailable antiviral agents
Yeung, Kap-Sun
Qiu, Zhilei
Xue, Quifen
Fang, Haiquan
Yang, Zheng
Zadjura, Lisa
D'Arienzo, Celia J.
Eggers, Betsy J.
Riccardi, Keith
Shi, Pei-Yong
Gong, Yi-Fei
Browning, Marc R.
Gao, Qi
Hansel, Steven
Santone, Kenneth
Lin, Ping-Fang
Meanwell, Nicholas A.
Kadow, John F.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (01) : 198 - 202
[42] Discovery and development of orally available subnanomolar potent checkpoint kinase 1 inhibitors as potential anticancer therapies
Vo, Alex C.
Taylor, Janelle
Rosier, Robert
Leviten, Dina
Sierra, Teresa
Boyce, Richard
Boyle, Robert
Peterson, Scott
Klucher, Kevin
CANCER RESEARCH, 2016, 76
[43] Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation
Arhancet, Graciela B.
Walker, Daniel P.
Metz, Sue
Fobian, Yvette M.
Heasley, Steven E.
Carter, Jeffrey S.
Springer, John R.
Jones, Darin E.
Hayes, Michael J.
Shaffer, Alexander F.
Jerome, Gina M.
Baratta, Michael T.
Zweifel, Ben
Moore, William M.
Masferrer, Jaime L.
Vazquez, Michael L.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (04) : 1114 - 1119
[44] Identifying Isoononin and Candidissiol as Rho-associated protein kinase 1 (ROCK1) inhibitors: a combined virtual screening and MD simulation approach
Alotaibi, Bader Saud
Joshi, Jatin
Hasan, Mohammad Raghibul
Khan, Mohd Shahnawaz
Alharethi, Salem Hussain
Mohammad, Taj
Alhumaydhi, Fahad A.
Elasbali, Abdelbaset Mohamed
Hassan, Md Imtaiyaz
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2023, 41 (14): : 6749 - 6758
[45] Rho Kinase Inhibitors as Potential Therapeutic Agents for Oncogenic KIT, FLT3, and BCR-ABL Induced Leukemogenesis
Mali, Raghuveer
Ramdas, Baskar
Munugalavadla, Veerendra
Sims, Emily
Kapur, Reuben
BLOOD, 2009, 114 (22) : 1503 - 1504
[46] Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase (vol 59, pg 6281, 2016)
Degorce, Sebastien L.
Barlaam, Bernard
Cadogan, Elaine
Dishington, Allan
Ducray, Richard
Glossop, Steven C.
Hassall, Lorraine A.
Lach, Franck
Lau, Alan
McGuire, Thomas M.
Nowak, Thorsten
Ouvry, Gilles
Pike, Kurt G.
Thomason, Andrew G.
JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (14) : 6398 - 6398
[47] Selective cyclooxygenase-2 inhibitors: Heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agents
Khanna, IK
Yu, Y
Huff, RM
Weier, RM
Xu, XD
Koszyk, FJ
Collins, PW
Cogburn, JN
Isakson, PC
Koboldt, CM
Masferrer, JL
Perkins, WE
Seibert, K
Veenhuizen, AW
Yuan, JH
Yang, DC
Zhang, YY
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (16) : 3168 - 3185
[48] Development and therapeutic potential of adaptor-associated kinase 1 inhibitors in human multifaceted diseases
Xin, Xin
Wang, Yue
Zhang, Lele
Zhang, Dan
Sha, Leihao
Zhu, Ziyu
Huang, Xiaoyi
Mao, Wuyu
Zhang, Jifa
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 248
[49] 3-(piperazinylpropyl)indoles:: Selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents
Chambers, MS
Street, LJ
Goodacre, S
Hobbs, SC
Hunt, P
Jelley, RA
Matassa, VG
Reeve, AJ
Sternfeld, F
Beer, MS
Stanton, JA
Rathbone, D
Watt, AP
MacLeod, AM
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (04) : 691 - 705
[50] Discovery of LC-MI-3: A Potent and Orally Bioavailable Degrader of Interleukin-1 Receptor-Associated Kinase 4 for the Treatment of Inflammatory Diseases
Chen, Lingfeng
Luo, Ruixiang
Ma, Lin
Xu, Ying
Cao, Jiaqi
Jiang, Zheng
Chen, Shiyan
Huang, Xiaohao
Zhang, Mingwan
Zheng, Lei
Zhang, Yawen
Yin, Lina
Yu, Jie
Zheng, Xiaochun
Zheng, Lulu
Huang, Ping
Liang, Guang
JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (10) : 8060 - 8076

← 1 2 3 4 5 →